<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002283</url>
  </required_header>
  <id_info>
    <org_study_id>007A</org_study_id>
    <nct_id>NCT00002283</nct_id>
  </id_info>
  <brief_title>A Comparison of Dapsone and Trimethoprim-Sulfamethoxazole in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS</brief_title>
  <official_title>Randomized Prospective Study of Dapsone Versus Trimethoprim-Sulfamethoxazole in the Treatment of First Episode Pneumocystis Carinii Pneumonia in AIDS Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jacobus Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      Evaluate the effectiveness rate of dapsone plus trimethoprim as a therapy for the first&#xD;
      episode of Pneumocystis carinii pneumonia (PCP) in AIDS patients. Compare the rates and&#xD;
      severity of adverse effects using dapsone versus trimethoprim - sulfamethoxazole (TMP /&#xD;
      PurposeX). Establish relative toxicities with regard to suitability for outpatient treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Pneumonia, Pneumocystis Carinii</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimethoprim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfamethoxazole</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapsone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Exclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Requirement for other medications found to be effective in the treatment of&#xD;
             Pneumocystis carinii pneumonia (PCP) (i.e., DFMO, pyrimethamine, and sulfadiazine).&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  History of allergic reaction to dapsone.&#xD;
&#xD;
          -  Requirement for other medications found to be effective in the treatment of&#xD;
             Pneumocystis carinii pneumonia (PCP) (i.e., DFMO, pyrimethamine, and sulfadiazine).&#xD;
&#xD;
          -  Patients subsequently found to be glucose-6-phosphate dehydrogenase (G6PD) positive&#xD;
             will be withdrawn from the study and treated with another regimen.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Requirement for other medications found to be effective in the treatment of&#xD;
             Pneumocystis carinii pneumonia (PCP) (i.e., DFMO, pyrimethamine, and sulfadiazine).&#xD;
&#xD;
        Patients who are glucose-6-phosphate dehydrogenase (G6PD) positive will be withdrawn from&#xD;
        the study and treated with another regimen.&#xD;
&#xD;
        Hospitalized patients with first episode of Pneumocystis carinii pneumonia (PCP) documented&#xD;
        by GIEMSA or methenamine stain.&#xD;
&#xD;
          -  Patients must:&#xD;
&#xD;
          -  Be willing and able to give informed consent.&#xD;
&#xD;
          -  Be expected to survive 1 week without therapy.&#xD;
&#xD;
          -  Have less than 48 hours of treatment for Pneumocystis carinii pneumonia (PCP) for this&#xD;
             episode.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Jacobus Pharmaceutical Co</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 1989</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Trimethoprim-Sulfamethoxazole Combination</keyword>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Pneumonia, Pneumocystis carinii</keyword>
  <keyword>Dapsone</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Pneumocystis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Dapsone</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

